{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041312","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.338295+00:00","generated_at":"2026-06-11T17:30:24.088991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Trevi Therapeutics Q2 net loss $7.1M; cash $94.2M; three chronic cough trials on track for H2 2023","bullets":["Net loss of $7.1M in Q2 2023 vs. $8.1M in Q2 2022; R&D expenses rose to $5.8M.","Cash, cash equivalents and marketable securities $94.2M at June 30, 2023.","Plans to initiate three chronic cough trials (Phase 2b IPF, Phase 1b IPF, Phase 2a RCC) in H2 2023 remain on track.","Human Abuse Potential study delayed due to IV butorphanol shortage from supplier tornado damage.","Phase 2 CANAL trial data published in NEJM Evidence; term loan of $6.5M repaid in May 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041312","json":"https://secwatch.observer/filing/0000950170-23-041312.json","markdown":"https://secwatch.observer/filing/0000950170-23-041312.md","text":"https://secwatch.observer/filing/0000950170-23-041312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023041312/0000950170-23-041312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023041312/trvi-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:30:24.088991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52e8ee195f7b218ba9590ae2e87036f95fff73bc","claim":"Trevi Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss: For the second quarter of 2023, the Company reported a net loss of $7.1 million, compared to a net loss of $8..","evidence_excerpt":"On August 10, 2023, Trevi Therapeutics, Inc., a Delaware corporation (the \"Company\") announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023041312/0000950170-23-041312-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss: For the second quarter of 2023, the Company reported a net loss of $7.1 million, compared to a net loss of $8."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}